Kronos Bio Zukünftiges Wachstum

NasdaqGS:KRON - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-85	-48	N/A	1
12/31/2025	2	-63	-49	N/A	3
12/31/2024	10	-76	-59	N/A	2
9/30/2024	10	-86	-78	-78	N/A
6/30/2024	8	-103	-88	-88	N/A
3/31/2024	8	-116	-97	-97	N/A
12/31/2023	6	-113	-79	-79	N/A
9/30/2023	4	-119	-77	-76	N/A
6/30/2023	3	-120	-76	-76	N/A
3/31/2023	1	-123	-74	-73	N/A
12/31/2022	N/A	-133	-92	-91	N/A
9/30/2022	N/A	-164	-128	-127	N/A
6/30/2022	N/A	-165	-127	-125	N/A
3/31/2022	N/A	-161	-126	-122	N/A
12/31/2021	N/A	-151	-122	-118	N/A
9/30/2021	N/A	-122	-82	-75	N/A
6/30/2021	N/A	-128	-76	-65	N/A
3/31/2021	N/A	-108	-60	-50	N/A
12/31/2020	N/A	-88	-47	-38	N/A
9/30/2020	N/A	-61	-34	-27	N/A
6/30/2020	N/A	-25	-24	-20	N/A
3/31/2020	N/A	-20	-22	-19	N/A
12/31/2019	N/A	-16	-18	-15	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KRON wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: KRON wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: KRON wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: KRONDie Einnahmen des Unternehmens (37.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: KRONDie Einnahmen des Unternehmens (37.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von KRON in 3 Jahren voraussichtlich hoch sein wird

Kronos Bio Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 62% to US$1.63

Consensus EPS estimates upgraded to US$1.35 loss

Price target decreased by 14% to US$9.00

Consensus revenue estimates decrease by 17%

Consensus revenue estimates increase by 17%, EPS downgraded

Price target increased by 7.5% to US$10.75

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Price target decreased by 62% to US$1.63

Kronos Bio Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

Kronos Bio, Inc. Announces Selection of Autoimmune Development Candidate for Sjogren's Disease

Consensus EPS estimates upgraded to US$1.35 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Kronos Bio, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2024

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

President recently bought US$734k worth of stock

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

President recently bought US$3.1m worth of stock

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio: Still Promising But Riskier Following ASCO Update

Kronos Bio, Inc. to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Kronos Bio, Inc. Appoints Deborah Knobelman as Chief Financial Officer, Effective June 3, 2024

Kronos Bio: Underestimated Drug Discovery Platform

Kronos Bio, Inc., Annual General Meeting, Jun 25, 2024

Kronos Bio Plans to Reduction in Force

New minor risk - Insider selling

Kronos Bio, Inc. Announces Executive Changes

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Kronos Bio, Inc. Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

President recently bought US$1.5m worth of stock

New minor risk - Share price stability

Kronos Bio to Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 Kb-0742 Study At the Connective Tissue Oncology Society Annual Meeting

Kronos Bio, Inc. Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study At AACR-NCI-EORTC

Kronos Bio, Inc. Appoints Sandra A. Gardiner as Principal Financial Officer and Principal Accounting Officer

Price target decreased by 14% to US$9.00

Consensus revenue estimates decrease by 17%

We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

Kronos Bio Announces Resignation of Yasir Al-Wakeel as Chief Financial Officer, Effective from September 15, 2023

Consensus revenue estimates increase by 17%, EPS downgraded

New minor risk - Shareholder dilution

Price target increased by 7.5% to US$10.75

Kronos Bio, Inc. Appoints Marc Besman as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance

Consensus revenue estimates decrease by 17%

Consensus EPS estimates upgraded to US$1.84 loss

We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Marianne De Backer to Resign from Board of Directors of Kronos Bio, Inc

Kronos Bio, Inc. Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting

Kronos Bio, Inc. Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial

Price target decreased to US$16.60

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio, Inc. Announces First Patient Dosed in Phase 1B/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia

Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

Kronos Bio, Inc.(NasdaqGS:KRON) dropped from Russell 2000 Growth Index

Price target decreased to US$25.25

President recently bought US$2.3m worth of stock

Price target decreased to US$31.25

Price target decreased to US$36.25

Kronos Bio, Inc. Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development

We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

Insider recently sold US$203k worth of stock

President recently bought US$173k worth of stock

Kronos Bio, Inc. Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia

Kronos Bio, Inc Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742

Chief Scientific Officer exercised options and sold US$161k worth of stock

Chief Scientific Officer exercised options and sold US$171k worth of stock

Chief Scientific Officer exercised options and sold US$159k worth of stock

Independent Director Jakob Loven has left the company

Kronos Bio, Inc. Announces Receipt of Minutes from the End-Of-Phase 2 Meeting with the U.S. Food and Drug Administration

How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

Kronos Bio, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

Kronos Bio, Inc. Enters into an Amendment to Its Office Lease Dated July 19, 2018 with MPVCA San Mateo LLC

Independent Director has left the company

Kronos Bio EPS misses by $4.10